Ovarian Cancer Clinical Trials in New York

Showing 181-200 of 269 trials

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

NCT02121990

The purpose of this study is to test the safety of the drug olaparib at different dose levels. It will be given with the standard initial chemotherapy for cancer as well as a drug called bevacizumab.

Ovarian CancerPrimary Peritoneal CancerFallopian Tube Cancer

Memorial Sloan Kettering Cancer Center17 participantsStarted Apr 2014

Basking Ridge, New Jersey, United States • Commack, New York, United States • Harrison, New York, United States +2 more locations

COMPLETED< 1 mile

Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer

NCT03656809

The purpose of this study is to determine the feasibility of routine referral to genetic counseling for all patients with a new diagnosis of epithelial ovarian, primary peritoneal or fallopian tube cancer.

Ovarian Cancer

NYU Langone Health125 participantsStarted Oct 2015

New York, New York, United States

COMPLETEDPhase 1< 1 mile

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

NCT03430518

This study will evaluate the recommended Phase 2 combination dose (RP2D) of eribulin with durvalumab.

HER2-Negative Metastatic Breast CancerRecurrent Ovarian Cancer

Amy Tiersten9 participantsStarted May 2018

New York, New York, United States

COMPLETEDPhase 2< 1 mile

Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer

NCT01611558

To assess the incidence of drug-related adverse events of Grade 3 or higher and the overall response associated with ipilimumab treatment

Platinum-sensitive Ovarian Cancer, Second-line, Third-line, or Fourth-line

Bristol-Myers Squibb40 participantsStarted Aug 2012

New Haven, Connecticut, United States • Orlando, Florida, United States • Tampa, Florida, United States +14 more locations

Dose-Escalation Study of Intraperitoneal (IP) Cisplatin, IV/IP Paclitaxel, IV Bevacizumab, and Oral Olaparib for Newly Diagnosed Ovarian, Primary Peritoneal, and Fallopian Tube Cancer

Feasibility of Multi-gene Panel Testing at the Time of Diagnosis for Patients With Ovarian Cancer

Durvalumab and Eribulin in Her2-negative Metastatic Breast Cancer and Recurrent Ovarian Cancer

Phase II Study of Ipilimumab Monotherapy in Recurrent Platinum-sensitive Ovarian Cancer

Ovarian Cancer Trials in Other Cities

Benchmarking Intra-tumor Heterogeneity In Ovarian Cancer: Linking In-vivo Imaging Phenotypes With Histology And Genomics

Cancer Screening and Prevention Program for High Risk Women

ISIS 5132 in Treating Patients With Metastatic or Recurrent Ovarian Cancer

Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients

Standard Infusion Carboplatin Versus Prophylactic Extended Infusion Carboplatin in Patients With Patients With Recurrent, Ovary, Fallopian Tube, and Primary Peritoneal Cancer

Pharmacokinetic Study of Avastin and Doxil in Ovarian Cancer

VTX-2337 and Pegylated Liposomal Doxorubicin (PLD) in Patients With Recurrent or Persistent Epithelial Ovarian, Fallopian Tube or Primary Peritoneal Cancer

Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell Cancer

Quality of Life and Care Needs of Patients With Persistent or Recurrent Ovarian Cancer, Fallopian Tube Cancer, or Peritoneal Cancer

Avelumab in Previously Untreated Patients With Epithelial Ovarian Cancer (JAVELIN OVARIAN 100)

Temsirolimus, Carboplatin, and Paclitaxel as First-Line Therapy in Treating Patients With Newly Diagnosed Stage III-IV Clear Cell Ovarian Cancer

A Study LY2228820 for Recurrent Ovarian Cancer

Phase 1b Safety Study of CMB305 in Patients With Locally Advanced, Relapsed, or Metastatic Cancer Expressing NY-ESO-1

Study of Ramucirumab in Ovarian Cancer

Open Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of CUDC-907 in Subjects With Advanced/Relapsed Solid Tumors

Study of Talazoparib, a PARP Inhibitor, in Patients With Advanced or Recurrent Solid Tumors

Other Conditions in New York